CN101362738B - 一种马来酸桂哌齐特的制备方法 - Google Patents
一种马来酸桂哌齐特的制备方法 Download PDFInfo
- Publication number
- CN101362738B CN101362738B CN200810161810XA CN200810161810A CN101362738B CN 101362738 B CN101362738 B CN 101362738B CN 200810161810X A CN200810161810X A CN 200810161810XA CN 200810161810 A CN200810161810 A CN 200810161810A CN 101362738 B CN101362738 B CN 101362738B
- Authority
- CN
- China
- Prior art keywords
- preparation
- piperazine
- reaction
- trimethoxy
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960004201 cinepazide Drugs 0.000 title claims abstract description 56
- XSTJTOKYCAJVMJ-GVTSEVKNSA-N (z)-but-2-enedioic acid;(e)-1-[4-(2-oxo-2-pyrrolidin-1-ylethyl)piperazin-1-yl]-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one Chemical compound OC(=O)\C=C/C(O)=O.COC1=C(OC)C(OC)=CC(\C=C\C(=O)N2CCN(CC(=O)N3CCCC3)CC2)=C1 XSTJTOKYCAJVMJ-GVTSEVKNSA-N 0.000 title claims abstract description 41
- 238000000034 method Methods 0.000 title description 11
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims abstract description 92
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 84
- 238000002360 preparation method Methods 0.000 claims abstract description 71
- -1 cinnamoyl Chemical group 0.000 claims abstract description 37
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000013078 crystal Substances 0.000 claims abstract description 14
- 238000002425 crystallisation Methods 0.000 claims abstract description 13
- 230000008025 crystallization Effects 0.000 claims abstract description 13
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims abstract description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 12
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000006243 chemical reaction Methods 0.000 claims description 68
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 60
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 51
- 238000003756 stirring Methods 0.000 claims description 46
- 229960005141 piperazine Drugs 0.000 claims description 39
- 235000019441 ethanol Nutrition 0.000 claims description 35
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000012141 concentrate Substances 0.000 claims description 23
- 238000001035 drying Methods 0.000 claims description 23
- 238000010992 reflux Methods 0.000 claims description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- CWGPCQYKWJWNIU-UHFFFAOYSA-N [ClH](CCCCCCCCCCCCCCC)C1CCN2CCCC12 Chemical compound [ClH](CCCCCCCCCCCCCCC)C1CCN2CCCC12 CWGPCQYKWJWNIU-UHFFFAOYSA-N 0.000 claims description 21
- 238000010438 heat treatment Methods 0.000 claims description 19
- RCUDFXMNPQNBDU-VOTSOKGWSA-N cinepazide Chemical compound COC1=C(OC)C(OC)=CC(\C=C\C(=O)N2CCN(CC(=O)N3CCCC3)CC2)=C1 RCUDFXMNPQNBDU-VOTSOKGWSA-N 0.000 claims description 17
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 15
- 239000000047 product Substances 0.000 claims description 14
- 238000005406 washing Methods 0.000 claims description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 12
- 150000005826 halohydrocarbons Chemical class 0.000 claims description 12
- 235000017550 sodium carbonate Nutrition 0.000 claims description 12
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 8
- ZOIHAPJGSMQVCR-UHFFFAOYSA-N 5-(3-chloroprop-1-enyl)-1,2,3-trimethoxybenzene Chemical compound COC1=CC(C=CCCl)=CC(OC)=C1OC ZOIHAPJGSMQVCR-UHFFFAOYSA-N 0.000 claims description 7
- IWTYTFSSTWXZFU-QPJJXVBHSA-N [(e)-3-chloroprop-1-enyl]benzene Chemical compound ClC\C=C\C1=CC=CC=C1 IWTYTFSSTWXZFU-QPJJXVBHSA-N 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 7
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims description 6
- 235000019082 Osmanthus Nutrition 0.000 claims description 6
- 241000333181 Osmanthus Species 0.000 claims description 6
- 230000006837 decompression Effects 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 6
- 238000011084 recovery Methods 0.000 claims description 6
- 238000001953 recrystallisation Methods 0.000 claims description 6
- 230000003068 static effect Effects 0.000 claims description 6
- 238000001291 vacuum drying Methods 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 238000012544 monitoring process Methods 0.000 claims description 5
- 239000012074 organic phase Substances 0.000 claims description 5
- MYNIYCGOBKAQAO-UHFFFAOYSA-N piperazine;sulfuric acid Chemical compound OS(O)(=O)=O.C1CNCCN1 MYNIYCGOBKAQAO-UHFFFAOYSA-N 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 4
- 229910021641 deionized water Inorganic materials 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 235000010755 mineral Nutrition 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 239000003880 polar aprotic solvent Substances 0.000 claims description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 3
- 235000015320 potassium carbonate Nutrition 0.000 claims description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims 2
- GCPRNIZDNTXQIX-NBPLQZBRSA-N 1-chloro-2-(2-chloroethylsulfanyl)ethane;dichloro-[(e)-3-chloroprop-2-enyl]arsane Chemical compound ClCCSCCCl.Cl\C=C\C[As](Cl)Cl GCPRNIZDNTXQIX-NBPLQZBRSA-N 0.000 claims 1
- 239000008346 aqueous phase Substances 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000007810 chemical reaction solvent Substances 0.000 claims 1
- 150000004885 piperazines Chemical class 0.000 claims 1
- YTFVRYKNXDADBI-SNAWJCMRSA-N 3,4,5-trimethoxycinnamic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1OC YTFVRYKNXDADBI-SNAWJCMRSA-N 0.000 abstract description 2
- YTFVRYKNXDADBI-UHFFFAOYSA-N O-Methylsinapic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1OC YTFVRYKNXDADBI-UHFFFAOYSA-N 0.000 abstract description 2
- OENBVACGHWHNJC-UHFFFAOYSA-N ClCC(=O)C1CCN2CCCC12 Chemical compound ClCC(=O)C1CCN2CCCC12 OENBVACGHWHNJC-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 150000001263 acyl chlorides Chemical class 0.000 abstract 1
- 239000012320 chlorinating reagent Substances 0.000 abstract 1
- 229910017053 inorganic salt Inorganic materials 0.000 abstract 1
- 238000002844 melting Methods 0.000 abstract 1
- 230000008018 melting Effects 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- DLCYXQODDJUHQL-VOTSOKGWSA-N (e)-3-phenyl-1-piperazin-1-ylprop-2-en-1-one Chemical compound C1CNCCN1C(=O)\C=C\C1=CC=CC=C1 DLCYXQODDJUHQL-VOTSOKGWSA-N 0.000 description 2
- LCXSXBYYVYTYDY-BTJKTKAUSA-N (z)-but-2-enedioic acid;piperazine Chemical compound C1CNCCN1.OC(=O)\C=C/C(O)=O LCXSXBYYVYTYDY-BTJKTKAUSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000033386 Buerger disease Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 229940114121 cinnamic acid preparation Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000007530 organic bases Chemical group 0.000 description 1
- 229960001893 piperazine sulfate Drugs 0.000 description 1
- NDPBYMFTBWPSNB-UHFFFAOYSA-N piperazine;sulfuric acid;hydrate Chemical compound O.OS(O)(=O)=O.C1CNCCN1 NDPBYMFTBWPSNB-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810161810XA CN101362738B (zh) | 2008-09-22 | 2008-09-22 | 一种马来酸桂哌齐特的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810161810XA CN101362738B (zh) | 2008-09-22 | 2008-09-22 | 一种马来酸桂哌齐特的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101362738A CN101362738A (zh) | 2009-02-11 |
CN101362738B true CN101362738B (zh) | 2011-01-26 |
Family
ID=40389369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200810161810XA Active CN101362738B (zh) | 2008-09-22 | 2008-09-22 | 一种马来酸桂哌齐特的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101362738B (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101591310B (zh) * | 2008-12-19 | 2012-03-21 | 王绍杰 | 一种马来酸桂哌齐特的制备方法 |
CN101492431B (zh) * | 2009-03-06 | 2011-05-18 | 王颖 | 马来酸桂哌齐特的制备方法 |
CN101955472B (zh) * | 2009-03-06 | 2012-11-14 | 王颖 | 马来酸桂哌齐特的制备方法 |
CN101531643B (zh) * | 2009-04-13 | 2012-11-14 | 上海理奥生物医药科技有限责任公司 | 一种改进的马来酸桂哌齐特的合成方法 |
CN101921247B (zh) * | 2009-06-12 | 2016-04-20 | 福州璐珈医药科技有限公司 | 1-(肉桂酰基)-4-哌啶基酰胺哌嗪化合物及其制备方法 |
CN101928265B (zh) * | 2009-06-24 | 2014-12-10 | 福州璐珈医药科技有限公司 | 1-(肉桂酰基)-4-烷基酰胺哌嗪化合物及其制备方法 |
CN101979386A (zh) * | 2009-12-17 | 2011-02-23 | 海南康虹医药科技开发有限公司 | 制备桂哌齐特游离碱的方法 |
CN101887050B (zh) * | 2010-06-18 | 2012-10-17 | 王颖 | 一种马来酸桂哌齐特中氯乙酰吡咯啶哌嗪的测定方法 |
CN103601700A (zh) * | 2013-12-05 | 2014-02-26 | 江苏黄河药业股份有限公司 | 一种磷酸哌嗪的制备方法 |
CN107632088A (zh) * | 2017-09-12 | 2018-01-26 | 河北智恒医药科技股份有限公司 | 一种马来酸桂哌齐特及其制剂中桂哌齐特氮氧化物的测定方法 |
CN112028856B (zh) * | 2019-06-03 | 2024-03-26 | 康普药业股份有限公司 | 一种马来酸桂哌齐特中间体的制备方法 |
-
2008
- 2008-09-22 CN CN200810161810XA patent/CN101362738B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN101362738A (zh) | 2009-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101362738B (zh) | 一种马来酸桂哌齐特的制备方法 | |
DE69723846T2 (de) | Verfahren zur Herstellung von Sildenafil | |
CN108314639B (zh) | 化合物(e)-3-(1-甲基吡咯烷-2-基)-丙烯酸盐酸盐及合成方法 | |
CN104945299B (zh) | 一种维格列汀的高效合成方法 | |
EA018227B1 (ru) | Способ получения дабигатрана и его промежуточные соединения | |
CN106905314A (zh) | 用于制备取代的5‑氟‑1h‑吡唑并吡啶类化合物的方法 | |
CN101279997A (zh) | 布地奈德的一种新的制备方法 | |
EP3257855B1 (en) | Method for preparing ibrutinib | |
CN105541844B (zh) | 一种高纯度利拉利汀的简易制备方法 | |
CN106496187A (zh) | 一种制备PARP抑制剂Niraparib的合成方法 | |
CN107434786A (zh) | 苯并咪唑化合物及其制备方法 | |
CN101538228A (zh) | 抗流感和禽流感病毒药物化合物帕拉米韦的合成方法 | |
JP6454669B2 (ja) | 1,4−ベンゾオキサジン化合物の製法 | |
BR112020001278A2 (pt) | processo aprimorado para preparar derivados de aminopirimidina | |
CN103923080A (zh) | 一种制备抗血栓药物阿哌沙班的方法 | |
EP3444253A1 (en) | Process for preparing ad-35 | |
CN101492431B (zh) | 马来酸桂哌齐特的制备方法 | |
DE10155018A1 (de) | Deuterierte Pyrazolopyrimidinone sowie diese Verbindungen enthaltende Arzneimittel | |
CN102731368B (zh) | 一种5,5-二氟-3-取代哌啶衍生物的制备方法 | |
DE60104704T2 (de) | Verfahren zur herstellung einer substituierten imidazopyridinverbindung | |
CN104262338B (zh) | 一种阿哌沙班及其中间体的合成方法 | |
CN101955472B (zh) | 马来酸桂哌齐特的制备方法 | |
EP3848361A1 (en) | Method of producing tetracyclic compound | |
CN109400507A (zh) | 艾拉莫德中间体杂质的合成 | |
CN109020900A (zh) | 6-氯-3-甲基尿嘧啶的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20091218 Address after: Dormitory 9-1-401, provincial medical college, 222 Dongfeng East Road, Hebei, Shijiazhuang Province, China: 050011 Applicant after: Zhao Junxu Co-applicant after: FUJIAN KINSAN BIOPHARMACEUTICAL CO.,LTD. Address before: Dormitory 9-1-401, provincial medical college, 222 Dongfeng East Road, Hebei, Shijiazhuang Province, China: 050011 Applicant before: Zhao Junxu |
|
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: FUJIAN JINSHAN BIOLOGICAL PHARMACEUTICAL CO., LTD. Owner name: FUJIAN JINSHAN BIOLOGICAL PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHAO JUNXU Effective date: 20100412 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 050011 9-1-401, PROVINCIAL ACADEMY OF MEDICAL SCIENCES DORMITORY, HEBEI PROVINCE, NO.222, DONGFENG EAST ROAD, SHIJIAZHUANG CITY, HEBEI PROVINCE TO: 350001 NO.3, GAOSHENG ROAD, CANGSHAN DISTRICT, FUZHOU CITY, FUJIAN PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20100412 Address after: 350001 No. 3, Goldman Road, Cangshan District, Fujian, Fuzhou Applicant after: FUJIAN KINSAN BIOPHARMACEUTICAL CO.,LTD. Address before: 050011 dormitory 9-1-401, provincial medical college, 222 Dongfeng East Road, Hebei, Shijiazhuang Applicant before: Zhao Junxu Applicant before: FUJIAN KINSAN BIOPHARMACEUTICAL CO.,LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221213 Address after: 13/F, Huoli Building, No. 3, Goldman Sachs Road, Cangshan District, Fuzhou City, 350000, Fujian Province Patentee after: Fuzhou Cornerstone Pharmaceutical Technology Co.,Ltd. Address before: 350001 No.3, Gaoshang Road, Cangshan District, Fuzhou City, Fujian Province Patentee before: FUJIAN KINSAN BIOPHARMACEUTICAL CO.,LTD. |
|
TR01 | Transfer of patent right |